United States Radiopharmaceuticals Market Set to Reach USD 2.36 Billion by 2033 | CAGR 6.30%

The United States Radiopharmaceuticals Market is at a critical juncture of scientific innovation and clinical urgency. Valued at USD 2.21 Billion in 2024, the market is on a firm trajectory toward USD 2.36 Billion by 2033, reflecting a CAGR of 6.30% during 2025–2033. The intersection of a rapidly aging population, a chronic disease epidemic affecting approximately 129 million Americans, and transformative advances in theranostics, AI-driven imaging, and targeted radiotherapy is reshaping what radiopharmaceuticals can deliver for patients and providers alike.

Healthcare decision-makers, oncology professionals, and life sciences investors are actively searching for “United States radiopharmaceuticals market outlook,” “theranostics growth USA 2026,” and “nuclear medicine investment opportunities” — signaling intense commercial engagement across the value chain. This press release delivers IMARC-verified data and actionable segment intelligence for professionals making consequential decisions in the United States radiopharmaceuticals market.

Explore Growth Opportunities in the United States radiopharmaceuticals market – Grab IMARC Sample Report for evaluation:

United States Radiopharmaceuticals Market at a Glance

•    Market Size (2024): USD 2.21 Billion
•    Market Forecast (2033): USD 2.36 Billion
•    Growth Rate (2025–2033 CAGR): 6.30%
•    Base Year: 2024
•    Forecast Window: 2025 to 2033
•    Historical Reference Period: 2019–2024

Where the United States Radiopharmaceuticals Market Is Headed in 2026

The year 2026 represents a pivotal inflection point for the United States radiopharmaceuticals market. Structural forces that have been building for years — the chronic disease burden, the theranostics paradigm shift, AI-powered imaging adoption, and federally supported nuclear medicine infrastructure expansion — are now converging into a compounding commercial reality. According to IMARC Group, the momentum established in 2026 is expected to sustain a 6.30% CAGR trajectory through 2033, with oncology, neurology, and personalized medicine driving the majority of incremental volume.
•    Approximately 129 million Americans live with one or more chronic conditions, with chronic diseases accounting for 90% of the annual USD 4.1 trillion U.S. healthcare cost burden — creating a vast and urgent addressable market for radiopharmaceutical diagnostics and therapeutics.
•    NorthStar Medical Radioisotopes’ 52,000 sq. ft. Dose Manufacturing Center in Beloit, Wisconsin — launched October 2024 — is the first U.S. facility with simultaneous multi-isotope commercial-scale production, securing supply of Ac-225, Lu-177, In-111, and Cu-64 for the expanding market.
•    Telix Pharmaceuticals’ collaboration with Subtle Medical (October 2024) combined PSMA-PET imaging with FDA-cleared AI that cuts PET scan time by up to 75%, dramatically improving workflow efficiency at U.S. imaging centers.
•    Best Cyclotron Systems announced plans in June 2024 to manufacture hundreds of cyclotrons annually across U.S., European, and Indian operations, directly expanding theranostics production capacity through 2026 and beyond.

Key Forces Driving Market Expansion in 2026

Chronic Disease Prevalence and Aging Population

The chronic disease epidemic is the foundational demand driver for the United States radiopharmaceuticals market. With 42% of Americans living with two or more chronic conditions and five of the top ten leading causes of death linked to preventable and treatable illnesses, the need for early, precise, and non-invasive diagnostic tools has never been greater. The aging U.S. population is further amplifying demand for radiopharmaceutical imaging across oncology, cardiology, and neurology applications, positioning nuclear medicine as an indispensable component of modern healthcare delivery.

Theranostics: The Convergence of Diagnostics and Targeted Therapy

Theranostics — the simultaneous use of radiopharmaceuticals for diagnosis and targeted treatment — is the single most transformative trend reshaping the United States radiopharmaceuticals market. Agents such as Lutetium-177 and Gallium-68 are enabling oncologists to image a tumor and deliver precise radiation therapy in a single treatment paradigm, dramatically reducing systemic side effects. Applications in prostate and neuroendocrine cancers are gaining significant clinical traction, supported by expanding manufacturing capacity and growing regulatory approval pipelines heading into 2026.

Artificial Intelligence Accelerating Imaging and Drug Discovery

AI is fundamentally reshaping how radiopharmaceuticals are developed, administered, and interpreted. FDA-cleared deep learning solutions are reducing PET scan times by up to 75% without compromising diagnostic quality, improving patient comfort and imaging center throughput simultaneously. Machine learning algorithms are also accelerating the identification of novel radiopharmaceutical compounds, compressing traditional drug discovery timelines. As AI integration deepens across the United States radiopharmaceuticals market, both diagnostic precision and therapeutic efficacy are improving at an unprecedented pace.

Government Support and Nuclear Medicine Infrastructure Investment

Federal and institutional investment in nuclear medicine infrastructure is actively addressing historic supply chain vulnerabilities in the United States radiopharmaceuticals market. The establishment of domestic multi-isotope production facilities, streamlined regulatory pathways for novel radiopharmaceuticals, and public-private partnerships supporting clinical trial activity are collectively reducing supply risk and accelerating commercial-scale availability of critical isotopes. This infrastructure build-out is expected to be a sustained market catalyst through the forecast period.

United States Radiopharmaceuticals Market Segmentation

IMARC Group provides granular forecasts for the United States radiopharmaceuticals market through 2025–2033. The market is categorized by product type, application, end use, and region.

By Product Type

•    Diagnostic Nuclear Medicine: The larger segment, encompassing PET and SPECT imaging agents such as Technetium-99m and Fluorine-18. Advances in molecular imaging technology are enhancing diagnostic accuracy across oncological, cardiovascular, and neurological applications, making early disease detection more accessible and actionable across the United States radiopharmaceuticals market.
•    Therapeutic Nuclear Medicine: A fast-growing segment driven by the theranostics revolution. Radioisotopes including Lutetium-177 and Iodine-131 are delivering targeted radiation to diseased cells with minimal impact on surrounding healthy tissue, representing the frontier of precision oncology for thyroid, prostate, and neuroendocrine cancers.

By Application

•    Oncology: The dominant application, accounting for the largest market share. Radiopharmaceuticals are central to cancer imaging and targeted radiotherapy, with theranostic approaches for prostate, thyroid, and neuroendocrine tumors representing the most dynamic growth sub-segment within the United States radiopharmaceuticals market.
•    Cardiology: Technetium-99m and related agents enable non-invasive myocardial perfusion imaging and coronary artery disease diagnosis. Growing cardiovascular disease prevalence and improvements in nuclear cardiac imaging technology are sustaining robust demand in this application category.
•    Neurology: Fluorine-18 and other radiotracers are enabling visualization of brain activity and early detection of biomarkers for Alzheimer’s, Parkinson’s, and epilepsy. Rising incidence of neurodegenerative conditions is making early non-invasive diagnosis increasingly critical and commercially significant.
•    Endocrinology: Iodine-131 remains the gold standard for thyroid imaging, hyperthyroidism management, and thyroid cancer treatment. Growing endocrine disorder prevalence and expanding radiopharmaceutical therapy approvals are driving continued segment growth.
•    Others: Emerging applications in pulmonology, orthopedics, and rare disease diagnostics are broadening the addressable scope of the United States radiopharmaceuticals market beyond its traditional core applications.

By End Use

•    Hospitals and Clinics: The largest end-use segment, anchored by advanced PET and SPECT imaging infrastructure and broad clinical expertise in nuclear medicine. Rising chronic disease burden and expanding therapeutic nuclear medicine programs are sustaining high radiopharmaceutical consumption volumes across this segment.
•    Research Institutes: Critical drivers of next-generation radiopharmaceutical innovation, conducting clinical trials, preclinical studies, and molecular imaging research. Academic-industry collaborations and personalized medicine initiatives are expanding the research institute segment’s commercial impact within the market.
•    Diagnostic Centers: Specialized imaging facilities offering focused PET and SPECT services are addressing the rising demand for non-invasive diagnostics in outpatient and community healthcare settings, expanding access beyond major hospital systems.

By Region

•    Northeast: A global center for oncology research, world-class academic medical centers, and nuclear medicine innovation. The Northeast leads in theranostic clinical trial activity and novel radiopharmaceutical regulatory approvals.
•    Midwest: Home to critical nuclear medicine manufacturing infrastructure, including NorthStar Medical Radioisotopes’ landmark Beloit facility. The Midwest is increasingly central to domestic isotope supply chain resilience for the United States radiopharmaceuticals market.
•    South: Rapidly expanding healthcare infrastructure and a large chronic disease patient population are driving above-average radiopharmaceutical demand growth across oncology and cardiology applications.
•    West: A hub for biotechnology and life sciences innovation, with California leading in radiopharmaceutical R&D investment, AI-imaging integration, and personalized medicine program development.

Competitive Landscape: Who’s Shaping the United States Radiopharmaceuticals Market
The United States radiopharmaceuticals market is shaped by a mix of global pharmaceutical leaders, specialized nuclear medicine manufacturers, and innovative biotech entrants. The three key players below represent the most significant competitive forces in the current landscape.

Lantheus Holdings, Inc.

A U.S.-headquartered leader in the development, manufacture, and commercialization of radiopharmaceuticals, Lantheus has built a dominant position across both diagnostic and emerging therapeutic nuclear medicine. Its PYLARIFY (18F-DCFPyL) PSMA-PET imaging agent has become one of the most widely adopted prostate cancer diagnostic tools in the country. Lantheus’ continued pipeline expansion into theranostics and targeted alpha therapy positions it at the forefront of the United States radiopharmaceuticals market heading into 2026.

NorthStar Medical Radioisotopes, LLC

The October 2024 launch of NorthStar’s 52,000 sq. ft. Dose Manufacturing Center in Beloit, Wisconsin — the first U.S. facility capable of simultaneous multi-isotope commercial-scale production — marks a transformational moment for domestic supply chain security. NorthStar’s ability to produce Ac-225, Lu-177, In-111, and Cu-64 from a single facility directly addresses critical isotope availability constraints that have historically limited market growth in the United States radiopharmaceuticals market.

Telix Pharmaceuticals Limited

An oncology-focused radiopharmaceutical company with a growing U.S. commercial presence, Telix has positioned its Illuccix (68Ga-PSMA-11) PSMA-PET imaging product as a leading tool for prostate cancer staging. Its October 2024 collaboration with Subtle Medical to integrate FDA-cleared AI technology — reducing PET scan time by up to 75% — exemplifies the company’s commitment to combining radiopharmaceutical innovation with digital health solutions to redefine clinical efficiency across the United States radiopharmaceuticals market.

Recent Market Developments

•    October 2024: NorthStar Medical Radioisotopes launched a 52,000 sq. ft. Dose Manufacturing Center in Beloit, Wisconsin — the first U.S. facility with simultaneous multi-isotope commercial-scale production capability, securing domestic supply of Ac-225, Lu-177, In-111, and Cu-64.
•    October 2024: Telix Pharmaceuticals partnered with Subtle Medical to integrate AI-powered SubtlePET technology with its Illuccix PSMA-PET product, reducing PET scan time by up to 75% while maintaining full diagnostic quality across U.S. imaging centers.
•    June 2024: Best Cyclotron Systems (TeamBest Global) announced plans to manufacture hundreds of cyclotrons annually across U.S., European, and Indian operations, with 10–15 advanced cyclotron deliveries planned in 2024 to expand theranostics and isotope production capacity globally.
•    March 2024: Siemens Healthineers unveiled its Cinematic Reality app on Apple Vision Pro at HIMSS 2024, offering immersive 3D medical imaging visualizations for surgical planning, medical education, and patient engagement — signaling the accelerating convergence of AI, imaging, and radiopharmaceuticals.

Where Smart Capital Is Looking in 2026

For investors, biopharma operators, and strategic buyers evaluating the United States radiopharmaceuticals market, the most compelling opportunity areas are:
•    Theranostic platform developers with clinical-stage Lutetium-177 and Actinium-225 programs targeting high-prevalence oncology indications including prostate, neuroendocrine, and liver cancers.
•    Domestic isotope manufacturing infrastructure, particularly multi-isotope production facilities that address supply chain resilience gaps exposed by global disruptions.
•    AI and digital health companies developing imaging workflow optimization, dose precision, and radiopharmaceutical compound identification tools for nuclear medicine applications.
•    Cyclotron and radiopharmacy network operators expanding access to on-demand PET radiopharmaceuticals in underserved regional markets across the South and Midwest.
•    Specialized contract development and manufacturing organizations (CDMOs) supporting the scale-up of novel radiopharmaceutical therapeutic candidates through clinical trials and commercial launch.

Questions Decision-Makers Are Asking

1.    What is the projected size and CAGR of the United States radiopharmaceuticals market through 2033?
2.    How is the theranostics paradigm reshaping both diagnostic and therapeutic nuclear medicine applications and competitive dynamics?
3.    Which application segments — oncology, cardiology, or neurology — will deliver the highest growth through the forecast period?
4.    How are domestic isotope manufacturing investments addressing supply chain vulnerabilities in the United States radiopharmaceuticals market?
5.    What role is artificial intelligence playing in improving imaging accuracy, workflow efficiency, and drug discovery timelines for radiopharmaceuticals?

What the Full IMARC Report Delivers

IMARC Group’s United States Radiopharmaceuticals Market Report 2026 is purpose-built for professionals who need rigorous, decision-ready intelligence:
•    Full market size forecasts and CAGR projections from 2025–2033 at the country and regional level
•    Detailed segment analysis across product type (Diagnostic, Therapeutic), application (Oncology, Cardiology, Neurology, Endocrinology, Others), and end use (Hospitals, Research Institutes, Diagnostic Centers)
•    Regional deep-dives covering Northeast, Midwest, South, and West with clinical infrastructure and demand intelligence
•    Competitive landscape mapping with profiles of all major radiopharmaceutical manufacturers, CDMOs, and emerging biotech entrants
•    Regulatory environment analysis covering FDA approval trends, PMTA pipelines, and theranostic clinical trial activity
•    Investment feasibility frameworks with supply chain risk analysis, isotope availability intelligence, and market entry strategy recommendations

Author IMARC Group
IMARC Group is a globally recognized market research and management consulting firm committed to helping organizations make smarter, faster decisions through data-driven intelligence. From market sizing and competitive benchmarking to feasibility studies and go-to-market strategy, IMARC equips businesses across industries with the insights they need to grow with confidence.

Get in Touch
IMARC Group
Email: sales@imarcgroup.com
U.S. Phone: +1-201-971-6302
UK: +44-753-714-6104